<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01041859</url>
  </required_header>
  <id_info>
    <org_study_id>CR016051</org_study_id>
    <secondary_id>R331333PAI3027</secondary_id>
    <secondary_id>KF56</secondary_id>
    <nct_id>NCT01041859</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Efficacy, Safety, and Tolerability of Tapentadol ER Compared With Placebo in Patients With Chronic, Painful Diabetic Peripheral Neuropathy</brief_title>
  <official_title>A Randomized-Withdrawal, Placebo-Controlled, Study Evaluating the Efficacy, Safety, and Tolerability of Tapentadol Extended-Release (ER) in Subjects With Chronic, Painful Diabetic Peripheral Neuropathy (DPN)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gr√ºnenthal GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy, safety, and tolerability of orally
      administered tapentadol extended release (ER) at dosages of 100 to 250 mg twice daily
      compared with placebo in patients with moderate to severe pain due to chronic, painful
      diabetic peripheral neuropathy (DPN) who tolerated tapentadol (ER) and have an initial
      treatment effect (pain improvement) after a 3-week, open-label titration period.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized-withdrawal (only patients that have an initial response to tapentadol
      are assigned to either tapentadol or placebo), placebo-controlled, multicenter study
      evaluating the efficacy, safety, and tolerability of orally administered tapentadol, using
      the extended release tamper-resistant formulation (TRF), at dosages of 100 to 250 mg twice
      daily in patients with moderate to severe pain due to chronic, painful DPN. The study
      consists of 1) an open-label (all people involved know the identity of the intervention)
      phase, including a 13-day screening period, a 5-day washout period (where patients are to
      stop taking their pain medication), a 3-day pre-titration pain-intensity evaluation period
      (where patients will record their pain intensity twice daily in the morning and evening), and
      a 3-week, open-label titration period (all patients receive tapentadol study drug), 2) a
      12-week, double-blind (neither physician nor patient knows the name of the assigned drug)
      maintenance phase, and 3) a posttreatment phase of approximately 10 to 14 days. The study
      will evaluate the effectiveness of orally administered tapentadol ER versus placebo in
      reducing patients' pain intensity. The pain intensity will be assessed by comparing the
      baseline pain level to the level at week 12 of the maintenance phase. The total duration of
      study drug treatment for each patient will be approximately 15 weeks. Safety and tolerability
      will be evaluated by vital signs, physical examinations, clinical laboratory tests, 12-lead
      electrocardiograms (ECGs), standardized neurologic examinations, and monitoring of adverse
      events. Patients will be titrated on tapentadol ER from a starting dose of 50 mg twice daily
      to the patient's optimal dose ranging between 100 mg and 250 mg twice a day, or placebo. All
      doses of study medication will be taken orally with approximately 120 ml of water with or
      without food for a maximum timeframe of 15 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Double-Blind Baseline of the Average Pain Intensity Based on an 11-point Numerical Rating Scale(NRS) Over the Last Week of the Maintenance Period at Week 12</measure>
    <time_frame>Double-Blind Baseline and 12 weeks (Primary endpoint is the average pain intensity score during the last week of the maintenance period)</time_frame>
    <description>For this twice daily pain assessment, the patients were to indicate the level of pain experienced over the previous 12 hours on an 11-point Numerical Rating Scale (NRS) where a score of 0 indicated &quot;no pain&quot; and a score of 10 indicated &quot;pain as bad as you can imagine&quot;.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Responder Analysis: Proportion of Patients With At Least 50% Improvement From Baseline of Open-Label on the Numerical Rating Scale (NRS) at the Week 12 Endpoint</measure>
    <time_frame>Open-label Baseline and End of Double-Blind Treatment at 15 Weeks (3 weeks open-label plus 12 weeks double-blind)</time_frame>
    <description>The NRS was a twice-daily pain assessment in which patients were to indicate the level of pain experienced over the previous 12 hours on an 11-point scale with a score of 0 indicating &quot;no pain&quot; and a score of 10 indicating &quot;pain as bad as you can imagine&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution of Patient Global Impression of Change at Week 12 Endpoint</measure>
    <time_frame>End of Double-Blind Treatment at 12 Weeks</time_frame>
    <description>Patient Global Impression of Change (PGIC) is a patient-rated assessment of overall neuropathic pain since the start of treatment using a categorical scale 1-7, where 1 is 'very much improved' and 7 is 'very much worse'</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline of Open-Label in the Pain Intensity Subscale of the Brief Pain Inventory (BPI) at the Week 12 Double-Blind Endpoint</measure>
    <time_frame>Open-label Baseline and End of Double-Blind Treatment at 15 Weeks (3 weeks open-label plus 12 weeks double-blind)</time_frame>
    <description>The BPI is a 12-item questionnaire to evaluate the intensity of pain and the degree to which pain interferes with function. It includes 4 items assessing current pain intensity and pain at its worst, least, and on average over the past day using an 11-point scale from 0 = no pain to 10 = pain as bad as you can imagine. The pain intensity subscale score is defined as the mean of the scores from these 4 items.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the EuroQoL-5 Dimension (EQ-5D) Health Status Index at the Week 12 Endpoint</measure>
    <time_frame>Double-blind Baseline and End of Double-Blind Treatment at 12 Weeks</time_frame>
    <description>EQ-5D has 5 items (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) rated on a categorical scale of 1-3 with 1=no problems, 2=some problems, 3=extreme problems. The health state index is a weighted combination of the 5 items. It has a range of 0 to 1, with 0=deceased and 1=full health.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">460</enrollment>
  <condition>Diabetic Peripheral Neuropathy</condition>
  <arm_group>
    <arm_group_label>Tapentadol Extended Release (ER)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tapentadol extended release (ER)</intervention_name>
    <description>Type= range, unit= mg, number= 100 to 250, form= tablet, route= oral use. Tapentadol ER optimal dose ranging between 100 mg and 250 mg twice daily for 15 weeks.</description>
    <arm_group_label>Tapentadol Extended Release (ER)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Form= tablet, route= oral use. Matching placebo twice daily.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with Type 1 or 2 diabetes mellitus must have a documented clinical diagnosis
             of painful diabetic peripheral neuropathy with symptoms and signs for at least 6
             months, and pain present at the time of screening

          -  Diagnosis must include pain plus reduction or absence of pin sensibility and/or
             vibration sensibility on Total Neuropathy Score - Nurse (TNSn) examination in lower
             and/or upper extremities at screening

          -  The investigator considers the patient's blood glucose to be controlled by diet, or
             hypoglycemics, or insulin for at least 3 months prior to enrolling in the study

          -  Patients have been taking analgesic medications for the condition for at least 3
             months prior to screening (patients taking opioid analgesics must be dissatisfied with
             current treatment, and patients taking non-opioid analgesics must be dissatisfied with
             current analgesia)

          -  Patients currently requiring opioid treatment must be taking daily doses of an
             opioid-based analgesic equivalent to &lt;=160mg of oral morphine

        Exclusion Criteria:

          -  Significant history of pulmonary, gastrointestinal, endocrine, metabolic (except
             diabetes mellitus), neurological, psychiatric disorders (resulting in disorientation,
             memory impairment or inability to report accurately as in schizophrenia)

          -  History of moderate to severe hepatic impairment

          -  Severely impaired renal function

          -  Clinically significant laboratory abnormalities

          -  Clinically significant cardiac disease

          -  History of seizure disorder or epilepsy

          -  History of any other clinically significant disease that in the investigator's opinion
             may affect efficacy or safety assessments or may compromise patient safety during
             study participation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C. Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orange</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Redding</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Spring Valley</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hallandale Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ormond Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St Petersburg</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Eagle</city>
        <state>Idaho</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Meridian</city>
        <state>Idaho</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Avon</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fishers</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Prairie Village</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Owings Mills</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pasadena</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brockton</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Edina</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cedarhurst</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Flushing</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ny</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Valley Stream</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Williamsville</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hickory</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Allentown</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Altoona</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Anderson</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Greer</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bulverde</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Odessa</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Schertz</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Alexandria</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Virginia Beach</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kelowna</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barrie</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hawkesbury</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sarnia</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sudbury</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dollard-Des-Ormeaux</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Laval</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Juan</city>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 30, 2009</study_first_submitted>
  <study_first_submitted_qc>December 30, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 1, 2010</study_first_posted>
  <results_first_submitted>March 8, 2012</results_first_submitted>
  <results_first_submitted_qc>April 13, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 14, 2012</results_first_posted>
  <last_update_submitted>August 29, 2013</last_update_submitted>
  <last_update_submitted_qc>August 29, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 11, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetic Peripheral Neuropathy</keyword>
  <keyword>Painful</keyword>
  <keyword>Polyneuropathy</keyword>
  <keyword>Peripheral neuropathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Nervous System Diseases</mesh_term>
    <mesh_term>Diabetic Neuropathies</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>In a 3-week open-label (OL) period, patients titrated to an optimal dose between 100 mg and 250 mg twice daily. Patients with &gt;=1-point reduction in pain intensity at the end of OL period were randomized. 38 of 358 who completed OL were not randomized: &lt;1-pt reduction(28), withdrew consent(4), non-compliant(2), adverse events(1), other reason(3).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>OL Tapentadol</title>
          <description>Tapentadol extended release (ER) 50 100 150 200 250 mg twice daily for 3 weeks</description>
        </group>
        <group group_id="P2">
          <title>DB Tapentadol ER</title>
          <description>Tapentadol extended release (ER) 100 150 200 250 mg twice daily for 12 weeks</description>
        </group>
        <group group_id="P3">
          <title>DB Placebo</title>
          <description>Double-Blind Placebo Control Group</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Open-Label Titration</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="459">Of 460 total enrollment, one subject enrolled twice; this subject's second enrollment is excluded.</participants>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="358">Of 358 completed subjects, 320 were randomized to the Double-Blind Maintenance Period.</participants>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="101"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="69"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Noncompliance With Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Double-Blind Maintenance</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="166">168 were randomized, 2 were not treated (1 randomized in error, 1 withdrew consent).</participants>
                <participants group_id="P3" count="152">152 randomized, all were treated.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="120"/>
                <participants group_id="P3" count="107"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="46"/>
                <participants group_id="P3" count="45"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="23"/>
                <participants group_id="P3" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Noncompliance With Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>DB Tapentadol ER</title>
          <description>Tapentadol extended release (ER) 100 150 200 250 mg twice daily for 12 weeks</description>
        </group>
        <group group_id="B2">
          <title>DB Placebo</title>
          <description>Double-Blind Placebo Control Group</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="166"/>
            <count group_id="B2" value="152"/>
            <count group_id="B3" value="318"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="122"/>
                    <measurement group_id="B2" value="109"/>
                    <measurement group_id="B3" value="231"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.5" spread="10.63"/>
                    <measurement group_id="B2" value="59" spread="9.00"/>
                    <measurement group_id="B3" value="58.7" spread="9.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                    <measurement group_id="B2" value="64"/>
                    <measurement group_id="B3" value="131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="99"/>
                    <measurement group_id="B2" value="88"/>
                    <measurement group_id="B3" value="187"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region Enroll</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>USA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="142"/>
                    <measurement group_id="B2" value="130"/>
                    <measurement group_id="B3" value="272"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Double-Blind Baseline of the Average Pain Intensity Based on an 11-point Numerical Rating Scale(NRS) Over the Last Week of the Maintenance Period at Week 12</title>
        <description>For this twice daily pain assessment, the patients were to indicate the level of pain experienced over the previous 12 hours on an 11-point Numerical Rating Scale (NRS) where a score of 0 indicated &quot;no pain&quot; and a score of 10 indicated &quot;pain as bad as you can imagine&quot;.</description>
        <time_frame>Double-Blind Baseline and 12 weeks (Primary endpoint is the average pain intensity score during the last week of the maintenance period)</time_frame>
        <population>Intent-to-treat (ITT) population. Last observation carried forward (LOCF) was used to impute pain score after discontinuation</population>
        <group_list>
          <group group_id="O1">
            <title>DB Tapentadol ER</title>
            <description>Tapentadol extended release (ER) 100 150 200 250 mg twice daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>DB Placebo</title>
            <description>Double-Blind Placebo Control Group</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Double-Blind Baseline of the Average Pain Intensity Based on an 11-point Numerical Rating Scale(NRS) Over the Last Week of the Maintenance Period at Week 12</title>
          <description>For this twice daily pain assessment, the patients were to indicate the level of pain experienced over the previous 12 hours on an 11-point Numerical Rating Scale (NRS) where a score of 0 indicated &quot;no pain&quot; and a score of 10 indicated &quot;pain as bad as you can imagine&quot;.</description>
          <population>Intent-to-treat (ITT) population. Last observation carried forward (LOCF) was used to impute pain score after discontinuation</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="165"/>
                <count group_id="O2" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.28" spread="2.04"/>
                    <measurement group_id="O2" value="1.3" spread="2.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The primary null hypothesis to be tested for the study was that the tapentadol ER group was not different from the placebo group for the primary endpoint. Assuming the mean treatment group difference of 1.0 with an SD of 2.6, 144 subjects per treatment group were estimated to provide 90% power to show that the tapentadol ER group was statistically different from placebo at an alpha level of 0.05. The total number of subjects to be randomly assigned to a DB treatment group for the study was 300.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Analysis of covariance (ANCOVA) model was used with treatment, dose level, and pooled analysis center as factors and baseline pain intensity score as a covariate</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.95</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.234</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.415</ci_lower_limit>
            <ci_upper_limit>-0.493</ci_upper_limit>
            <estimate_desc>Mean Difference is least squares mean change in DB Tapentadol ER group minus least squares mean change in DB Placebo group (based on ANCOVA model)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Responder Analysis: Proportion of Patients With At Least 50% Improvement From Baseline of Open-Label on the Numerical Rating Scale (NRS) at the Week 12 Endpoint</title>
        <description>The NRS was a twice-daily pain assessment in which patients were to indicate the level of pain experienced over the previous 12 hours on an 11-point scale with a score of 0 indicating &quot;no pain&quot; and a score of 10 indicating &quot;pain as bad as you can imagine&quot;.</description>
        <time_frame>Open-label Baseline and End of Double-Blind Treatment at 15 Weeks (3 weeks open-label plus 12 weeks double-blind)</time_frame>
        <population>Intent-to-treat (ITT) population. Last observation carried forward (LOCF) was used to impute pain score after discontinuation.</population>
        <group_list>
          <group group_id="O1">
            <title>DB Tapentadol ER</title>
            <description>Tapentadol extended release (ER) 100 150 200 250 mg twice daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>DB Placebo</title>
            <description>Double-Blind Placebo Control Group</description>
          </group>
        </group_list>
        <measure>
          <title>Responder Analysis: Proportion of Patients With At Least 50% Improvement From Baseline of Open-Label on the Numerical Rating Scale (NRS) at the Week 12 Endpoint</title>
          <description>The NRS was a twice-daily pain assessment in which patients were to indicate the level of pain experienced over the previous 12 hours on an 11-point scale with a score of 0 indicating &quot;no pain&quot; and a score of 10 indicating &quot;pain as bad as you can imagine&quot;.</description>
          <population>Intent-to-treat (ITT) population. Last observation carried forward (LOCF) was used to impute pain score after discontinuation.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="166"/>
                <count group_id="O2" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.4" spread="2.04"/>
                    <measurement group_id="O2" value="28.9" spread="2.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Distribution of Patient Global Impression of Change at Week 12 Endpoint</title>
        <description>Patient Global Impression of Change (PGIC) is a patient-rated assessment of overall neuropathic pain since the start of treatment using a categorical scale 1-7, where 1 is ‚Äòvery much improved‚Äô and 7 is ‚Äòvery much worse‚Äô</description>
        <time_frame>End of Double-Blind Treatment at 12 Weeks</time_frame>
        <population>Intent-to-treat (ITT) population. Last observation carried forward (LOCF) end point</population>
        <group_list>
          <group group_id="O1">
            <title>DB Tapentadol ER</title>
            <description>Tapentadol extended release (ER) 100 150 200 250 mg twice daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>DB Placebo</title>
            <description>Double-Blind Placebo Control Group</description>
          </group>
        </group_list>
        <measure>
          <title>Distribution of Patient Global Impression of Change at Week 12 Endpoint</title>
          <description>Patient Global Impression of Change (PGIC) is a patient-rated assessment of overall neuropathic pain since the start of treatment using a categorical scale 1-7, where 1 is ‚Äòvery much improved‚Äô and 7 is ‚Äòvery much worse‚Äô</description>
          <population>Intent-to-treat (ITT) population. Last observation carried forward (LOCF) end point</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="150"/>
                <count group_id="O2" value="139"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Very much improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.7" spread="2.04"/>
                    <measurement group_id="O2" value="14.4" spread="2.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Much improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.3"/>
                    <measurement group_id="O2" value="30.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Minimally improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.3"/>
                    <measurement group_id="O2" value="20.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not changed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0"/>
                    <measurement group_id="O2" value="18.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Minimally worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0"/>
                    <measurement group_id="O2" value="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Much worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3"/>
                    <measurement group_id="O2" value="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very much worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3"/>
                    <measurement group_id="O2" value="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline of Open-Label in the Pain Intensity Subscale of the Brief Pain Inventory (BPI) at the Week 12 Double-Blind Endpoint</title>
        <description>The BPI is a 12-item questionnaire to evaluate the intensity of pain and the degree to which pain interferes with function. It includes 4 items assessing current pain intensity and pain at its worst, least, and on average over the past day using an 11-point scale from 0 = no pain to 10 = pain as bad as you can imagine. The pain intensity subscale score is defined as the mean of the scores from these 4 items.</description>
        <time_frame>Open-label Baseline and End of Double-Blind Treatment at 15 Weeks (3 weeks open-label plus 12 weeks double-blind)</time_frame>
        <population>Intent-to-treat (ITT) population. Last observation carried forward (LOCF) endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>DB Tapentadol ER</title>
            <description>Tapentadol extended release (ER) 100 150 200 250 mg twice daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>DB Placebo</title>
            <description>Double-Blind Placebo Control Group</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline of Open-Label in the Pain Intensity Subscale of the Brief Pain Inventory (BPI) at the Week 12 Double-Blind Endpoint</title>
          <description>The BPI is a 12-item questionnaire to evaluate the intensity of pain and the degree to which pain interferes with function. It includes 4 items assessing current pain intensity and pain at its worst, least, and on average over the past day using an 11-point scale from 0 = no pain to 10 = pain as bad as you can imagine. The pain intensity subscale score is defined as the mean of the scores from these 4 items.</description>
          <population>Intent-to-treat (ITT) population. Last observation carried forward (LOCF) endpoint.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="137"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.0" spread="2.16"/>
                    <measurement group_id="O2" value="-2.3" spread="2.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the EuroQoL-5 Dimension (EQ-5D) Health Status Index at the Week 12 Endpoint</title>
        <description>EQ-5D has 5 items (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) rated on a categorical scale of 1-3 with 1=no problems, 2=some problems, 3=extreme problems. The health state index is a weighted combination of the 5 items. It has a range of 0 to 1, with 0=deceased and 1=full health.</description>
        <time_frame>Double-blind Baseline and End of Double-Blind Treatment at 12 Weeks</time_frame>
        <population>Intent-to-treat (ITT) population. Last observation carried forward (LOCF) endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>DB Tapentadol ER</title>
            <description>Tapentadol extended release (ER) 100 150 200 250 mg twice daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>DB Placebo</title>
            <description>Double-Blind Placebo Control Group</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the EuroQoL-5 Dimension (EQ-5D) Health Status Index at the Week 12 Endpoint</title>
          <description>EQ-5D has 5 items (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) rated on a categorical scale of 1-3 with 1=no problems, 2=some problems, 3=extreme problems. The health state index is a weighted combination of the 5 items. It has a range of 0 to 1, with 0=deceased and 1=full health.</description>
          <population>Intent-to-treat (ITT) population. Last observation carried forward (LOCF) endpoint.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="146"/>
                <count group_id="O2" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.203"/>
                    <measurement group_id="O2" value="-0.10" spread="0.257"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>OL Tapentadol</title>
          <description>Tapentadol extended release (ER) 50 100 150 200 250 mg twice daily for 3 weeks</description>
        </group>
        <group group_id="E2">
          <title>DB Tapentadol ER</title>
          <description>Tapentadol extended release (ER) 100 150 200 250 mg twice daily for 12 weeks</description>
        </group>
        <group group_id="E3">
          <title>DB Placebo</title>
          <description>Double-Blind Placebo Control Group</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 13.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="459"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Coronary Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="459"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Angina Unstable</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="459"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="459"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Coronary Artery Disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="459"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Coronary Artery Occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="459"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Myocardial Ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="459"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="459"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vision Blurred</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="459"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal Disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="459"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="459"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="459"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="459"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="459"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="459"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="459"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Diabetic Foot Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="459"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Gastroenteritis Viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="459"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="459"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Localised Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="459"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Necrotising Fasciitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="459"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="459"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="459"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Skull Fractured Base</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="459"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Subdural Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="459"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Traumatic Brain Injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="459"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Electrocardiogram Change</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="459"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="459"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="459"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="459"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="459"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Diabetes Mellitus Inadequate Control</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="459"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="459"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Balance Disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="459"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="459"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="459"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="459"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="459"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Suicidal Ideation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="459"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary Retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="459"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pleural Effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="459"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="459"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="459"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dry Gangrene</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="459"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="459"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Coronary Arterial Stent Insertion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="459"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Coronary Artery Bypass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="459"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Arterial Stenosis Limb</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="459"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="459"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="459"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 13.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="296" subjects_at_risk="459"/>
                <counts group_id="E2" subjects_affected="86" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="37" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="112" subjects_at_risk="459"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="459"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="459"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="459"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="459"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="459"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="459"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="78" subjects_at_risk="459"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="459"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="459"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="459"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="459"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="459"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The sponsor can embargo results from a PI's center until the combined results from the completed study have been published in full or the sponsor confirms there will be no multicenter study publication. Results communications must be provided to the sponsor for review at least 60 days before submission for publication. By written request, the sponsor can extend the embargo up to an additional 60 days. The sponsor cannot require changes to scientific content and cannot further extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Director, Clinical Leader</name_or_title>
      <organization>Janssen Research&amp;Development</organization>
      <phone>609-730-6777</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

